Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MacroGenics, Inc. before investing.

In this article, we go over a few key elements for understanding MacroGenics, Inc.’s stock price such as:

• MacroGenics, Inc.’s current stock price and volume
• Why MacroGenics, Inc.’s stock price changed recently
• Upgrades and downgrades for MGNX from analysts
• MGNX’s stock price momentum as measured by its relative strength

About MacroGenics, Inc. (MGNX)

Before we jump into MacroGenics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Want to learn more about MacroGenics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MacroGenics, Inc..

MacroGenics, Inc.’s Stock Price as of Market Close

As of March 27, 2026, 4:00 PM, CST, MacroGenics, Inc.’s stock price was $2.930.

MacroGenics, Inc. is down 7.86% from its previous closing price of $3.180.

During the last market session, MacroGenics, Inc.’s stock traded between $2.850 and $3.190. Currently, there are approximately 63.28 million shares outstanding for MacroGenics, Inc..

MacroGenics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MacroGenics, Inc. Stock Price History

MacroGenics, Inc.’s (MGNX) price is currently up 47.24% so far this month.

During the month of March, MacroGenics, Inc.’s stock price has reached a high of $3.540 and a low of $1.810.

Over the last year, MacroGenics, Inc. has hit prices as high as $3.540 and as low as $0.990. Year to date, MacroGenics, Inc.’s stock is up 81.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MacroGenics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 27, 2026, there was 1 analyst who downgraded MacroGenics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate MacroGenics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MacroGenics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

MacroGenics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MacroGenics, Inc. (MGNX) by visiting AAII Stock Evaluator.

Relative Price Strength of MacroGenics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 27, 2026, MacroGenics, Inc. has a weighted four-quarter relative price strength of 38.91%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how MacroGenics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MacroGenics, Inc. Stock Price: Bottom Line

As of March 27, 2026, MacroGenics, Inc.’s stock price is $2.930, which is down 7.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MacroGenics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.